Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Novo Nordisk to Limit Price Increases to Single-Digit Percentages

By Mike Botta | December 7, 2016

The president of Novo Nordisk Inc. says the company will limit future list-price increases for its medicines to no more than single-digit percentages annually. The move follows a similar pledge made by Allergan back in September.

In a statement on the company’s website, Novo Nordisk president Jakob Riis labeled the move a “position on affordability” and outlined three tenets: creating more pricing predictability, transforming the drug pricing system, and reducing the burden of out-of-pocket costs to patients.

Regarding pricing predictability, Riis said the company was taking the step so that customers and payers can effectively anticipate and budget for price increases. 

“News reports on drug prices have left the public with an impression that companies like ours realize all the profits from the ‘list price’ increases we’ve made over the last decade,” Riis said, terming such a notion “misleading” even though, as a manufacturer, the company sets the list price.

“However, after we set the list price, we negotiate with the companies that actually pay for the medicines, which we call payers,” Riis said in the statement, adding that it is a necessary in order for Novo Nordisk medicines drugs to remain on preferred drug lists. “The price or profit we receive after rebates, fees and other price concessions we provide to the payer is the “net price.” The net price more closely reflects our actual profits.”

Pointing to rebates, discounts and price concessions sought by pharmacy benefit managers and payers., he said the company was losing considerable revenue that otherwise would go to R&D, sales and marketing, education, disease awareness activities and medical information support. 

“So, we would continue to increase the list in an attempt to offset the increased rebates, discounts and price concessions to maintain a profitable and sustainable business,” he said. “While we can debate who pays what in different scenarios, it doesn’t change the fact that many patients simply can’t afford the medicine they need.”

Riis called for a partnership approach involving pharmacy benefit managers, insurance companies, employers, patient organizations and policy makers to help find sustainable solutions. 

“As a leader in diabetes care, we recognize patients need more,” he said in the website statement, promising that the company plans to have further discussions on the subject in coming months.

(Source: Novo Nordisk Inc.)

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE